Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · June 26, 2024

Risk of Diabetic Retinopathy and Diabetic Macular Oedema With SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

Diabetologia

 

Additional Info

Diabetologia
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
Diabetologia 2024 Jul 01;67(7)1271-1282, A Eleftheriadou, D Riley, SS Zhao, P Austin, G Hernández, GYH Lip, TL Jackson, JPH Wilding, U Alam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading